Prospoctive cohort of high-dose cyclophosphamide exposed patients. With active estandardize screening of hyponatremia development in the follow up period.
Primary objectives 1. To identify the factors associated with the development of hyponatremia in patients receiving high-dose cyclophosphamide (2.5 grams or more). 2. Generate and validate a predictive score of developing hyponatremia high-dose cyclophosphamide. 3. To estimate the incidence of hyponatremia in patients undergoing high-dose cyclophosphamide. Study design. Observational prospective cohort study of Patients after infusion of high-dose cyclophosphamide. Follow up period will be from cyclophosphamide infusion until one month after hospital discharge.
Study Type
OBSERVATIONAL
Enrollment
200
Hospital Italiano de Buenos Aires, Peron 4190
Buenos Aires, Buenos Aires F.D., Argentina
Hyponatremia
Hyponatremia, measured as any value sodium after infusion and defined as positive if sodium less than 135 mEq / l (Yes / No, dichotomous categorical variable). For the incidence of hyponatremia is only included in the calculation hionatremia patients with normal sodium before infusion.
Time frame: Between 6 and 8 hours after the infusion of cyclophosphamide is performed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.